Data updated: Mar 10, 2026
VYLEESI (AUTOINJECTOR)
BREMELANOTIDE ACETATE
Approved 2019-06-21
1
Indication
--
Phase 3 Trials
6
Years on Market
Details
- Status
- Prescription
- First Approved
- 2019-06-21
- Routes
- SUBCUTANEOUS
- Dosage Forms
- SOLUTION
VYLEESI (AUTOINJECTOR) Approval History
Loading approval history...
What VYLEESI (AUTOINJECTOR) Treats
1 FDA approvalsOriginally approved for its first indication in 2019 .
- Other (1)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VYLEESI (AUTOINJECTOR) FDA Label Details
ProVYLEESI (AUTOINJECTOR) Patents & Exclusivity
Latest Patent: Apr 2041
Patents (4 active)
US11590209
Expires Apr 29, 2041
US9352013
Expires Nov 5, 2033
US9700592
Expires Nov 5, 2033
US10286034
Expires Nov 5, 2033
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.